Genetic analysis for stratification and discovery in dementia patients by extending the NOMALY framework to non-coding variation

OutSee Limited working with Astex Pharmaceuticals will be unlocking value and insights in non-coding genomic data through the _Nomaly_ approach to support precision medicine for dementia patients. We will be developing new AI to tackle the non-coding part of the genome alongside discovery developed on the protein-coding variation in the genome. Dementia is a heterogeneous condition and includes multiple subtypes affecting memory, behaviour and cognitive abilities. Patient stratification into distinct subgroups is key to optimise treatment options so that interventions can be offered to those who will benefit the most and identify patient subgroups who are at risk. Subsequently, it would improve the clinical outcomes and reduce risks of adverse effects.